for food safety rules and human health risk measures taken by national health and veterinary agencies. Regarding adequate processing of clinical samples and their preservation for morphologic and genetic evaluation, we strongly recommend fixation of positive fecal samples with eggs or segments (proglottids) immediately with 96%–99% molecular grade (i.e., not denatured) ethanol for future molecular diagnosis (1,4–8).

This work was supported by the Czech Science Foundation (grant number 201/12/2932) and the Institute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic (grant number RVO: 60077344).

Roman Kuchta, José-Guillermo Esteban, Jan Brabec, and Tomáš Scholz

Author affiliations: Institute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic, České Budějovice, Czech Republic (R. Kuchta, J. Brabec, T. Scholz); and Facultad de Farmacia, Universidad de Valencia, Valencia, Spain (J.-G. Esteban)

DOI: http://dx.doi.org/10.3201/eid2011.140996

References


Address for correspondence: Roman Kuchta, Institute of Parasitology, Biology Centre of the Academy of Sciences of the Czech Republic, Branišovská 31, 370 05, České Budějovice, Czech Republic; email: krtek@paru.cas.cz

Drug Resistance in Salmonella enterica ser. Typhimurium Bloodstream Infection, Malawi

To the Editor: Salmonella enterica serotype Typhimurium is one of the most common causes of bloodstream infection in sub-Saharan Africa (1). Among adults, the principal risk factor for invasive nontyphoidal Salmonella (iNTS) disease is advanced HIV infection; up to 44% of HIV-infected patients experience bacteremic recurrence through recrudescence of the original infection (2,3). Epidemics of iNTS disease in sub-Saharan Africa have been associated with a novel genotype of S. enterica ser. Typhimurium of multilocus sequence type (ST) 313 that is rarely seen outside the region and is associated with multidrug resistance (MDR) to chloramphenicol, cottomoxazole, and ampicillin (4,5). As a consequence, ceftriaxone has become a key agent in the empirical management of nonfocal sepsis in Malawi (6).

In March 2009, a 40-year-old HIV-infected and antiretroviral therapy–naïve woman sought care in Blantyre, Malawi, with an MDR S. enterica ser. Typhimurium bloodstream infection. She was treated with ceftriaxone (2 g intravenously once daily) and discharged with oral ciprofloxacin (500 mg twice daily) for 10 days. She was readmitted 1 month later with recurrent fever. At this time, she had an MDR S. enterica ser. Typhimurium bloodstream infection with additional resistance to ceftriaxone and ciprofloxacin. In the absence of a locally available effective antimicrobial drug, she was treated with ceftriaxone, gentamicin, and high-dose ciprofloxacin but died shortly thereafter.

To help clarify how this extended MDR S. enterica ser. Typhimurium emerged, we determined the molecular mechanisms underpinning this disturbing pattern of antimicrobial resistance.
We conducted phenotypic drug susceptibility testing by disk diffusion on *S. enterica* ser. Typhimurium strains A54285 (initial presentation) and A54560 (recurrence); both isolates were resistant to ampicillin, chloramphenicol, and cotrimoxazole, but A54560 exhibited additional resistance to ceftriaxone, ciprofloxacin, and tetracycline.

Paired-end sequencing of isolates A54285 (European Nucleotide Archive [ENA] accession number ERS035867) and A54560 (ENA accession no. ERS035866) that were cultured 1 month apart showed no differences between the conserved regions of these genomes (Figure). The similarity of these *S. enterica* ser. Typhimurium genomes strongly suggests that this recrudescence occurred after incomplete clearance of the first infection; although re-infection from the same source is unlikely, it cannot be excluded. Comparison of the accessory genomes, however, showed an additional 300 kb DNA in A54560.

Plasmid extraction and gel electrophoresis of genomic DNA identified a plasmid migrating in the gel to a position approximately equivalent to 120 kb, the size of ST313 virulence plasmid pSLT-BT in both strains, but no 300-kb plasmid was visualized in the ceftriaxone- and ciprofloxacin-resistant strain (A54560, data not shown), possibly because of the difficulty large plasmids have entering standard 1% agarose gels. However, ceftriaxone resistance was mobilized to *Escherichia coli* by conjugation at a frequency $6.5 \times 10^{-2}$ transconjugants per donor at 26°C. This frequency dropped dramatically to $\approx 1 \times 10^{-7}$ transconjugants per donor when conjugation was performed at 37°C. The presence of an IncHI2 plasmid in the transconjugants was confirmed by PCR for the IncHI2 region (7), and drug susceptibility testing confirmed that transconjugant clones acquired resistance to ceftriaxone, ciprofloxacin, and tetracycline.

These data confirm the presence of an extended-spectrum b-lactamase (ESBL)–producing IncHI2 plasmid in strain A54560 that is capable of conjugative transfer and suggest that the plasmid might have been acquired by residual index strain within the patient by transfer from an unknown donor.
bacterium. Partial decolonization of the patient’s gastrointestinal tract by ceftriaxone and fluoroquinolone antimicrobial therapy might have rendered it receptive to colonization by ESBL-producing bacteria, which we hypothesize donated the plasmid to the residual index strain.

The transconjugant plasmid DNA was sequenced by using the PacBio RSII platform (Pacific Biosciences, Menlo Park, CA, USA; http://www.pacificbiosciences.com), which assembled as a single contiguous sequence of 309,406 bp, designated pSTm-BTCR (online Technical Appendix Figure, ENA accession no. LK056646). We identified 331 predicted coding sequences, including 109 genes required for replication and transfer and 61 genes predicted to be associated with metabolism, membranes, virulence, antimicrobial resistance, and a toxin/antitoxin addiction system. We found an additional 160 predicted coding sequences, resembling as a single contiguous sequence of 309,406 bp, designated LK056646. We identified 331 predicted coding sequences, including 109 genes required for replication and transfer and 61 genes predicted to be associated with metabolism, membranes, virulence, antimicrobial resistance, and a toxin/antitoxin addiction system. We found an additional 160 predicted, hypothetical genes. Fifteen putative antimicrobial resistance genes were identified, predicted to encode resistance to; tetracycline (tetA(C), tetR(C)), b-lactams (blaCTX-M15, blaTEM-13, blaOXA-30), chloramphenicol (catB3, catA1), aminoglycosides (strA, strB, aadA1, aac4, aac3), ciprofloxacin (qnrB1), sulfonamides (su2), and trimethoprim (dfrA14).

In our experience, ESBL and fluoroquinolone-resistant iNTS remain extremely uncommon in Blantyre, Malawi. This is surprising because diverse ESBL genotypes were observed in other members of Enterobacteriaceae in Blantyre within a year after ceftriaxone came into common use locally (8). That IncH112 plasmids transfer most efficiently at temperatures <30°C (9), a lower temperature than that in the human gastrointestinal tract, might explain why the acquisition of ESBL-producing enzymes through IncH112 plasmids has not been commonly observed within patients with recurrent iNTS disease in this setting. However, rates of transfer might differ when bacteria are growing in the intestine.

The spread of mobile genetic elements that confer antimicrobial resistance among gram-negative organisms is of considerable concern. Wide dissemination of this strain or the IncH12 (pSTm-BTCR) plasmid among other salmonellae in sub-Saharan Africa would rapidly render iNTS effectively untreatable with currently available antibacterial drugs.

This work was supported by the Wellcome Trust; N.A.F holds a Wellcome Research Training Fellowship. The Malawi Liverpool Wellcome Trust Clinical Research Programme and the Wellcome Trust Sanger Institute are core funded by the Wellcome Trust.

Nicholas A. Feasey, Amy K. Cain, Chisomo L. Msefula, Derek Pickard, Maaike Alaerts, Martin Aslett, Dean B. Everett, Theresa J. Allain, Gordon Dougan, Melita A. Gordon, Robert S. Heyderman, and Robert A. Kingsley

Author affiliations: Liverpool School of Tropical Medicine, Liverpool, UK (N.A. Feasey, R.S. Heyderman); Wellcome Trust Sanger Institute, Cambridge, UK (N.A. Feasey, A.K. Cain, D. Pickard, M. Aslett, G. Dougan, R.A. Kingsley); University of Malawi College of Medicine, Blantyre, Malawi (N.A. Feasey, C.L. Msefula, M. Alaerts, D.B. Everett, T.J. Allain, R.S. Heyderman); University of Liverpool, Liverpool (D.B. Everett, M.A. Gordon); and Institute of Food Research, Colney, Norwich, UK (R.A. Kingsley)

DOI: http://dx.doi.org/10.3201/eid2011.141175

References


